All In MedTech

FDA Clearance Tracker · DEN240071

neuropacs

A De Novo grant creates a new device type for a low to moderate risk device with nothing on the market to compare it to. Later devices of this type can use it as their comparison in a 510(k).

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this decision)Source: openFDAMethods & limitations

De NovoNew device type

The decision

FDA number
DEN240071
Device name
neuropacs
Applicant location
Gainesville, FL
Received
Dec 4, 2024
Decided
Apr 3, 2026
Decision
De Novo granted
Submission type
Direct

Device type

Device class
Class II
Regulation
21 CFR 882.2000

Every decision under product code SHO

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Automated Imaging Diagnostics, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.